Skip to content
HelixEVOLabs home
Sign in
HelixEVO LabsTesamorelin40 mgLOT ________For research use only. Not for human or veterinary use.STORE 2–8 °CHelixEVO LabsTesamorelin40 mgLOT ________For research use only.Not for human or veterinary use.STORE 2–8 °C
Research peptide

Tesamorelin

Tesamorelin

Specification
Total quantity
40 mg
Pack
Sealed glass vial(s); vial count confirmed before release
Form
Lyophilised powder
Stated purity
Reported per lot on the certificate of analysis
Appearance
White to off-white lyophilised powder in a sealed glass vial under an aluminium crimp seal.
Storage
2–8 °C, sealed, protected from light
Shipping
Dispatched from the United Kingdom Monday to Wednesday only, under cold chain in insulated packaging with coolant, so that no consignment is held over a weekend in transit.
SKU
HX-TESA-40
AvailabilityOut of stock

Pricing releasing soon. Leave an email to be told once, or request a wholesale quote now.

Request a wholesale quote
For laboratory research use only. Not for human or veterinary consumption.

Analytical data

Latest released lotNo released lot yet

Analytical data appear here as soon as the first lot is released. Every released lot carries a certificate with HPLC purity and MS identity per compound.

Method

Purity by reversed-phase HPLC with UV detection; identity by electrospray mass spectrometry against the calculated monoisotopic or average mass. Endotoxin where stated. The certificate names the laboratory and the method for every result.

How to read a certificate →

Identity

Identity · Tesamorelinverified 2026-09-21
In this product
40 mg
Synonyms
TH9507, TH-9507, (3E)-Hex-3-enoylsomatoliberin (human), N-((3E)-1-oxo-3-hexenyl)somatoliberin (human pancreatic islet), Egrifta, Egrifta SV, Egrifta WR, tesamorelina, tesamoreline, tesamorelinum
CAS
218949-48-5· PubChem, National Library of Medicine, FDA / NCATS Global Substance Registration System
UNII
MQG94M5EEO· FDA / NCATS Global Substance Registration System, PubChem, National Library of Medicine
PubChem CID
16137828
Formula
C221H366N72O67S· PubChem, National Library of Medicine, DailyMed, National Library of Medicine (label by Theratechnologies Inc.)
Mol. weight
5135.9 g/mol· DailyMed, National Library of Medicine (label by Theratechnologies Inc.), PubChem, National Library of Medicine
Class
Synthetic peptide; growth hormone-releasing factor (GRF/GHRH) analogue; ATC H01AC06
Targets
Growth hormone-releasing factor (GRF/GHRH) receptor on pituitary somatotrophs (agonist)
Modifications
Human GRF/GHRH(1-44) amide sequence with a trans-3-hexenoyl group (C6 chain, double bond at position 3) attached to the N-terminal tyrosine; C-terminal leucinamide. Prepared as an acetate salt.
Sequence (one-letter) · 44 residues
  1. Y
  2. A
  3. D
  4. A
  5. I
  6. F
  7. T
  8. N
  9. S
  10. Y
  11. R
  12. K
  13. V
  14. L
  15. G
  16. Q
  17. L
  18. S
  19. A
  20. R
  21. K
  22. L
  23. L
  24. Q
  25. D
  26. I
  27. M
  28. S
  29. R
  30. Q
  31. Q
  32. G
  33. E
  34. S
  35. N
  36. Q
  37. E
  38. R
  39. G
  40. A
  41. R
  42. A
  43. R
  44. L

Research overview

Tesamorelin, developed under the code TH9507, is a synthetic 44-residue analogue of human growth hormone-releasing factor (GRF, also called GHRH) in which a trans-3-hexenoyl group is attached to the N-terminal tyrosine and the C-terminal residue is a leucinamide 12. The FDA substance registry encodes exactly those two structural modifications and records no disulfide bridge and no glycosylation site 2. The N-terminal acylation is the pharmacologically relevant change: no degradation was observed on incubation with dipeptidyl peptidase-IV, and the in vitro half-life in human plasma was reported as several-fold that of unmodified hGRF 1. The compound sits in the GHRH-analogue family that the World Anti-Doping Agency groups under section S2.2.4 with CJC-1293, CJC-1295 and sermorelin 3. Identity exists as two records that a certificate must distinguish: the free base, CAS 218949-48-5, UNII MQG94M5EEO, formula C221H366N72O67S and 5136 g/mol; and the acetate salt, CAS 901758-09-6, UNII LGW5H38VE3, for which no source states a weight as supplied 456. As research context, the compound was examined in two randomised phase 3 trials with re-randomised extensions, later pooled, and in smaller randomised academic studies 789. In the United States the acetate is the active ingredient of a licensed prescription product, while searches of the two United Kingdom registers returned no record 101112.

  1. 1.Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol (2007). doi:10.1111/j.1742-7843.2007.00008.x
  2. 2.TESAMORELIN (UNII MQG94M5EEO) substance record. FDA / NCATS Global Substance Registration System (2026). source
  3. 3.The Prohibited List (2026): S2 Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency (2026). source
  4. 4.Tesamorelin (CID 16137828). PubChem, National Library of Medicine (2026). source
  5. 5.TESAMORELIN ACETATE (UNII LGW5H38VE3) substance record. FDA / NCATS Global Substance Registration System (2026). source
  6. 6.Tesamorelin acetate [USAN] (CID 44147413). PubChem, National Library of Medicine (2026). source
  7. 7.Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med (2007). doi:10.1056/NEJMoa072375
  8. 8.Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab (2010). doi:10.1210/jc.2010-0490
  9. 9.Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV (2019). doi:10.1016/S2352-3018(19)30338-8
  10. 10.Drugs@FDA: BLA 022505 EGRIFTA (tesamorelin acetate), Theratechnologies. US Food and Drug Administration (2026). source
  11. 11.MHRA Products: search results for 'tesamorelin'. Medicines and Healthcare products Regulatory Agency (2026). source
  12. 12.electronic medicines compendium (eMC): search results for 'tesamorelin'. Datapharm (eMC) (2026). source
Tesamorelin monograph

Regulatory status

Regulatory status · TesamorelinActive substance of a licensed medicine

This material is a research-grade chemical. It is not a medicinal product, has not been manufactured under GMP for medicinal use, and is not the licensed medicine whose active substance shares its name. It is supplied for laboratory research only.

The regulatory rows below describe the authorisation status of medicines containing this substance in each jurisdiction. They say nothing about this material, which is not authorised for any use in or on humans or animals.

United Kingdom
No record found: searches for 'tesamorelin' and 'egrifta' in the MHRA Products database, and for 'tesamorelin' on eMC, returned no results on 2026-09-21.Checked 2026-09-21 · Medicines and Healthcare products Regulatory Agency
European Union
Not authorised: the centralised marketing authorisation application for Egrifta (EMEA/H/C/002427, applicant Ferrer Internacional S.A.) was withdrawn on 21 June 2012.Checked 2026-09-21 · European Medicines Agency
United States
Approved prescription biological product (BLA 022505, Theratechnologies; original approval 10 November 2010) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.Checked 2026-09-21 · US Food and Drug Administration
WADA Prohibited List
Prohibited at all times: tesamorelin is named as an example of a GHRH analogue under S2.2.4 (growth hormone releasing factors) of the WADA Prohibited List.Checked 2026-09-21 · World Anti-Doping Agency
Handling and safety

Handle as a research chemical of unknown hazard in a laboratory setting with appropriate protective equipment. Keep sealed at 2–8 °C and protected from light. Safety data sheet: available on request until the SDS is published here.

Shipping

Dispatched in insulated cold-chain packaging with a coolant, Monday to Wednesday, to laboratory and business addresses within the United Kingdom. Destination rules are on the shipping policy.

Questions

Does this material correspond to the free base or the acetate record?
The two are distinct registry entries and the lot certificate states which applies. The free base is CAS 218949-48-5, UNII MQG94M5EEO, formula C221H366N72O67S; the acetate is CAS 901758-09-6, UNII LGW5H38VE3, with acetic acid recorded as the salt-forming agent [gsrs-tesamorelin-2026][gsrs-tesamorelin-acetate-2026].
Which molecular weight should a certificate quote?
For the free base, 5136 g/mol for formula C221H366N72O67S [pubchem-cid-16137828-2026]. No source states a weight for the acetate as supplied: PubChem models a 1:1 salt at 5196 g/mol, which does not describe a material of unspecified acetate content [pubchem-cid-44147413-2026]. Anti-doping method work reports a monoisotopic mass of 5132.7 for the intact peptide [knoop-2016-anal-bioanal-chem].
How is purity determined and what does the certificate of analysis show?
Chromatographic purity is determined by reversed-phase high-performance liquid chromatography with identity confirmed by mass spectrometry, and the lot certificate records the method, the chromatogram, the mass spectrum, net peptide content and the lot number. Published method work identifies the intact peptide by liquid chromatography with high-resolution tandem mass spectrometry [knoop-2016-anal-bioanal-chem].
Are published solubility or solution-stability figures available?
No usable figure exists for the unformulated peptide. No solubility statement appears in the identity records or in the regulatory documentation retrieved for the dossier, and every published solution figure describes a licensed finished formulation with its own excipients [pubchem-cid-16137828-2026][gsrs-tesamorelin-2026]. Both fields are therefore recorded as null rather than filled from unsourced figures.
How is the material presented and stored before shipping?
As lyophilised powder in a sealed glass vial, held at 2 to 8 °C and protected from light until dispatch. The pack quantity is stated as total mass in the specification panel. Vials are sealed at fill and are not opened again before shipping.